
Nicolle J M Besselink

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6683668/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Ovarian Cancer Cell Line Panel (OCCP): Clinical Importance of In Vitro Morphological Subtypes. PLoS ONE, 2014, 9, e103988.	2.5	319
2	5-Fluorouracil treatment induces characteristic T>G mutations in human cancer. Nature Communications, 2019, 10, 4571.	12.8	143
3	GRIDSS2: comprehensive characterisation of somatic structural variation using single breakend variants and structural variant phasing. Genome Biology, 2021, 22, 202.	8.8	73
4	Deficiency of nucleotide excision repair is associated with mutational signature observed in cancer. Genome Research, 2019, 29, 1067-1077.	5.5	66
5	The mutational impact of culturing human pluripotent and adult stem cells. Nature Communications, 2020, 11, 2493.	12.8	61
6	Measuring mutation accumulation in single human adult stem cells by whole-genome sequencing of organoid cultures. Nature Protocols, 2018, 13, 59-78.	12.0	52
7	Comparison of Next-Generation Sequencing and Mutation-Specific Platforms in Clinical Practice. American Journal of Clinical Pathology, 2015, 143, 573-578.	0.7	41
8	Reconstructing single-cell karyotype alterations in colorectal cancer identifies punctuated and gradual diversification patterns. Nature Genetics, 2021, 53, 1187-1195.	21.4	37
9	Simultaneous Detection of Clinically Relevant Mutations and Amplifications for Routine Cancer Pathology. Journal of Molecular Diagnostics, 2015, 17, 10-18.	2.8	35
10	Genome-wide analysis of somatic noncoding mutation patterns in cancer. Science, 2022, 376, eabg5601.	12.6	33
11	The molecular genetic make-up of male breast cancer. Endocrine-Related Cancer, 2019, 26, 779-794.	3.1	27
12	Early divergence of mutational processes in human fetal tissues. Science Advances, 2019, 5, eaaw1271.	10.3	24
13	Prioritization of genes driving congenital phenotypes of patients with de novo genomic structural variants. Genome Medicine, 2019, 11, 79.	8.2	19
14	Precancerous liver diseases do not cause increased mutagenesis in liver stem cells. Communications Biology, 2021, 4, 1301.	4.4	9
15	<i>TP53</i> mutated glioblastoma stem-like cell cultures are sensitive to dual mTORC1/2 inhibition while resistance in <i>TP53</i> wild type cultures can be overcome by combined inhibition of mTORC1/2 and Bcl-2. Oncotarget, 2016, 7, 58435-58444.	1.8	8
16	Fibroblast growth factor receptor signaling in pediatric B-cell precursor acute lymphoblastic leukemia. Scientific Reports, 2019, 9, 1875.	3.3	7
17	Effective Therapeutic Intervention and Comprehensive Genetic Analysis of mTOR Signaling in PEComa: A Case Report. Anticancer Research, 2015, 35, 3399-403.	1.1	2